Table 1.

Patient baseline demographics and clinical characteristics

	Glasdegib dose
	25 mg n = 3		50 mg n = 4		100 mg n = 6		Total
	Male	Female	Male	Female	Male	Female
Number of patients	2	1	3	1	3	3	13
Age, years
Median	64.5	49.0	68.0	65.0	73.0	68.0	68.0
Range	63–66	49–49	64–72	65–65	71–81	55–72	49–81
ECOG PS, n (%)
0	1 (33)		2 (50)		4 (67)		7 (54)
1	2 (67)		2 (50)		1 (17)		5 (38)
2	0		0		1 (17)		1 (8)
Primary diagnosis, n (%)
MDS	2 (67)		1 (25)		1 (17)		4 (31)
MF	0		0		1 (17)		1 (8)
CMML	0		1 (25)		0		1 (8)
AML	1 (33)		2 (50)		4 (67)		7 (54)
Prior regimens, n (%)
1	1 (33)		2 (50)		3 (50)		6 (46)
2	1(33)		0		1 (17)		2 (15)
3	0		1 (25)		0		1 (8)
>3	1 (33)		1 (25)		2 (33)		4 (31)

AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance score; MDS, myelodysplastic syndrome; MF, myelofibrosis.